Core Insights - The European Medicines Agency's CHMP has approved a label update for DARZALEX® (daratumumab) allowing self-administration by patients or caregivers from the fifth dose, marking it as the first oncology injectable approved for self-administration in Europe [1][12]. Group 1: Approval and Impact - The approval applies to all ten therapeutic indications of daratumumab SC for multiple myeloma, smouldering multiple myeloma, and light chain (AL) amyloidosis, providing greater flexibility in treatment administration [2][3]. - This decision is expected to reduce the burden on healthcare systems by allowing patients to receive treatment in a more convenient manner, thus enhancing their quality of life [3]. Group 2: Historical Context and Innovation - Daratumumab has been a foundational therapy in multiple myeloma treatment since its first approval nearly a decade ago, with over 748,000 patients treated worldwide [6][12]. - The drug utilizes Halozyme's ENHANZE® drug delivery technology, co-formulated with recombinant human hyaluronidase PH20, enabling subcutaneous administration [6]. Group 3: Patient Demographics and Disease Overview - In the European Union, over 35,000 new cases of multiple myeloma were diagnosed in 2022, with more than 22,700 deaths attributed to the disease [7][20]. - Multiple myeloma is characterized by the proliferation of malignant plasma cells in the bone marrow, leading to various complications such as bone destruction and anemia [7][20].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached $306 million, representing a 64% year-over-year growth [22] - Gross margin remained strong at 61%, with CARVYKTI net product sales gross margin at 57% [22] - Operating margin improved from -142% in Q2 2023 to -6% in Q4 2025, reflecting operational leverage [22][24] - Adjusted net income was reported at $2.5 million, a significant improvement from a $59 million adjusted net loss a year ago [24] Business Line Data and Key Metrics Changes - CARVYKTI net trade sales were approximately $555 million in Q4 2025, a 66% increase year-over-year [5][14] - U.S. net trade sales of CARVYKTI were $420 million, growing 38% year-over-year [14] - Outside the U.S., sales reached $135 million, representing over a threefold increase compared to the same period last year [14] Market Data and Key Metrics Changes - CARVYKTI is now offered in 14 global markets, with 294 treatment sites worldwide [14] - The majority of CARVYKTI patients (approximately 65%) are from the second to fourth line settings [14][76] - BCMA-directed therapies remain under-penetrated in earlier lines, with less than 5% of patients in the second through fourth line treated with a BCMA targeting agent in 2025 [15] Company Strategy and Development Direction - The company aims to achieve company-wide profitability in 2026, following CARVYKTI's profitability in 2025 [5][13] - Focus on expanding CARVYKTI's use in earlier treatment lines, supported by clinical evidence showing better outcomes [15][20] - Plans to file one to two U.S. INDs by the end of the year and to explore synergistic business development opportunities [12][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sequential growth throughout 2026, targeting approximately 50% top-line growth for CARVYKTI [30] - The company is optimistic about capturing a significant market share in the under-penetrated multiple myeloma market [15][45] - Management highlighted the importance of effective bridging therapy in improving patient outcomes and safety [19][90] Other Important Information - The company ended the year with $949 million in cash equivalents, providing flexibility for future investments [25] - Manufacturing capacity has been expanded to support annual production of 10,000 doses, with plans to increase to 20,000 doses [11][52] Q&A Session Summary Question: Expectations for CARVYKTI growth in 2026 and business development focus - Management expects sequential growth throughout 2026, confident in achieving approximately 50% top-line growth [30] - Business development efforts will focus on complementary technologies and potential partnerships to accelerate global development [31] Question: Positioning of bispecifics in early lines relative to CARVYKTI - Management noted a significant unmet need in second and third lines, with CARVYKTI's unique value proposition supporting its growth in these settings [34] Question: Community setting expansion hurdles - Continued education and training for community physicians are essential for expanding CARVYKTI's adoption in community hospitals [39][40] Question: Current CAR-T penetration targets - Management believes there is significant growth potential in both late and early lines, with plans to increase annual supply to meet demand [45][47] Question: Competitive dynamics following recent M&A in the space - The acquisition of a competitor validates the market's value, with management confident in CARVYKTI's unmatched efficacy and durability [59][61] Question: Pipeline strategy and in vivo programs - The company is particularly excited about in vivo CAR T approaches due to their convenience and potential for broader applications [82]

Core Insights - Johnson & Johnson announced FDA approval for TECVAYLI® plus DARZALEX FASPRO® for treating relapsed/refractory multiple myeloma, potentially establishing a new standard of care as early as the second line of treatment [1][2] - The approval is based on Phase 3 MajesTEC-3 study data, showing significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard treatments [1][2] Company Overview - Johnson & Johnson is a leader in multiple myeloma therapies, emphasizing its commitment to transforming treatment landscapes for this disease [1][2] - The company has a history of innovation in hematology, aiming to improve patient outcomes and accessibility to effective therapies [1][2] Treatment Efficacy - TECVAYLI® in combination with DARZALEX FASPRO® demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a three-year PFS rate of 83% versus 30% in the control arm [1][2] - The combination therapy showed higher rates of overall response (89% vs. 75.3%), complete response (81.8% vs. 32.1%), and minimal residual disease negativity (58.4% vs. 17.1%) at three years [1][2] Study Details - The MajesTEC-3 study is a randomized Phase 3 trial evaluating the safety and efficacy of teclistamab plus daratumumab against standard treatment options in patients with relapsed/refractory multiple myeloma [2] - The study's primary endpoint is PFS, with secondary endpoints including overall response rate, minimal residual disease negativity, and overall survival [2] Market Impact - The approval enhances treatment options for multiple myeloma patients, allowing for personalized treatment plans and potentially improving care accessibility [1][2] - Johnson & Johnson's new regimen is expected to address the critical need for effective therapies in patients experiencing multiple relapses [1][2] Future Aspirations - The company aims to continue advancing its multiple myeloma portfolio, with aspirations of ultimately curing the disease [1][2]

Core Insights - The FDA has approved DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant, marking the twelfth indication for DARZALEX FASPRO and the fifth in the newly diagnosed setting [1][3][8] Group 1: Approval and Efficacy - D-VRd demonstrated significantly deeper and more durable responses, higher minimal residual disease (MRD) negativity, and improved progression-free survival compared to the standard VRd regimen [1][3] - The pivotal Phase 3 CEPHEUS study showed that D-VRd increased the overall MRD-negativity rate to 52.3% versus 34.8% with VRd at a sensitivity threshold of 10 [2][4] - At a median follow-up of 39 months, the sustained MRD-negativity rate of 12 months was 42.6% for D-VRd compared to 25.3% for VRd [4] Group 2: Safety and Adverse Events - The overall safety profile of DARZALEX FASPRO combined with VRd was consistent with known adverse reactions for both components, with common adverse events including upper respiratory tract infection, sensory neuropathy, and musculoskeletal pain [5][28] - Serious infections occurred in 24% of patients, with pneumonia being the most common serious infection reported at 8.5% [21][28] - Injection-site reactions were reported in 8% of patients, with the most frequent being erythema and rash [20][28] Group 3: Study Details and Patient Population - The CEPHEUS study was a multicenter, randomized, open-label Phase 3 trial that enrolled 395 patients across 13 countries, focusing on those newly diagnosed with multiple myeloma who were ineligible for ASCT [6] - The primary endpoint was the overall MRD-negativity rate, with secondary endpoints including complete response rates and progression-free survival [6] Group 4: Background on Multiple Myeloma - Multiple myeloma is the second most common blood cancer globally, with an estimated 36,000 new diagnoses in the U.S. in 2026 and a 5-year survival rate of 59.8% [7]

Core Insights - Regeneron Pharmaceuticals has reported promising results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic™ (linvoseltamab) for newly diagnosed multiple myeloma (NDMM) patients, demonstrating a VGPR+ rate of ≥70% across all dose groups [2][4][3] - The trial is significant as it is the first to assess a BCMAxCD3 bispecific monotherapy in NDMM, aiming to simplify treatment regimens and improve tolerability [3][4] - Lynozyfic has shown a high rate of minimal residual disease (MRD) negativity, with 95% of evaluable VGPR+ patients achieving MRD negative status [4][5] Company Overview - Regeneron is a leading biotechnology company focused on developing innovative medicines for serious diseases, including blood cancers [36][30] - The company utilizes its proprietary VelocImmune technology to create fully human antibodies, which are integral to its drug development efforts [35][33] Clinical Development - The LINKER-MM4 trial is part of a broader clinical development program for Lynozyfic, which includes various ongoing trials exploring its use as both monotherapy and in combination with other treatments [6][13] - The trial involved a dose escalation and expansion approach, with 45 patients treated across different dose levels [4][3] Treatment Efficacy - Lynozyfic monotherapy has achieved MRD negativity rates comparable to traditional quadruplet regimens but earlier in the treatment course, indicating its potential as a foundational treatment for multiple myeloma [3][4] - The median time to onset of response across all dose levels was 1.2 months, with responses expected to deepen over time [4][3] Safety Profile - The most common treatment-emergent adverse events included cytokine release syndrome (CRS) and neutropenia, with no Grade 4 infections or dose-limiting toxicities reported [5][4] - Infections were noted in 84% of patients, primarily occurring within the first three months of treatment, but the rate decreased over time [5][4] Future Outlook - Regeneron plans to host a virtual investor event to discuss its multiple myeloma development program, highlighting the ongoing advancements in its clinical pipeline [8][2] - The company is committed to exploring Lynozyfic's potential across various lines of therapy for multiple myeloma and related conditions [13][6]

Financial Data and Key Metrics Changes - In Q3 2025, CARVYKTI net trade sales reached approximately $524 million, representing an 84% year-over-year increase [7][17] - Total revenues for the quarter were $272 million, driven by collaboration revenue growth of 84% year-over-year [26] - The company reported a net loss of $40 million, with an adjusted net loss of $19 million after excluding non-core items [27][29] - Operating loss improved by 38% to $43 million compared to the same period last year [28] Business Line Data and Key Metrics Changes - CARVYKTI's U.S. net trade sales were $396 million, growing 53% year-over-year and 11% quarter-over-quarter [18] - International sales reached $128 million, nearly five times the amount from the same period last year, representing a 58% quarter-over-quarter increase [18] - The company has treated over 9,000 patients with CARVYKTI, marking it as the strongest CAR-T launch to date [7][15] Market Data and Key Metrics Changes - The U.S. market saw 60% utilization of CARVYKTI in earlier line settings [18] - The number of authorized treatment centers in the U.S. increased to 132, with about one-third being community and regional hospitals [22] - The company launched in 14 markets globally, with strong uptake in Germany, Spain, and Belgium [87] Company Strategy and Development Direction - The company aims to solidify its leadership in cell therapy and expand CARVYKTI into frontline settings [15][16] - Plans include increasing manufacturing capacity to support demand, targeting 10,000 annualized doses [19][41] - The company is focused on educating physicians about CARVYKTI's overall survival benefits and the importance of early treatment [21][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability for CARVYKTI by the end of 2025 and company-wide profitability in 2026 [16][29] - The company is optimistic about the long-term growth potential in both the U.S. and international markets [15][87] - Management highlighted the importance of effective bridging therapies to mitigate adverse events and improve patient outcomes [66] Other Important Information - The FDA approved an update to CARVYKTI's label to include overall survival benefits [9] - The company is investing in operational efficiency and disciplined expense management to support long-term growth [25][29] Q&A Session Summary Question: How will the company prioritize cash allocation in 2026? - The company plans to maximize the CARVYKTI franchise and invest in manufacturing and CAR-T platform growth [33] Question: What is the status of the Raritan site expansion? - The expansion is on track for completion, with the facility expected to support 10,000 doses annually [36] Question: What are the expectations for authorized treatment centers in 2026? - The company aims to expand coverage to match competitors, targeting over 160 sites [40] Question: How will the company mobilize demand in a supply-constrained environment? - The focus will be on educating physicians about the benefits of early treatment and leveraging community networks [44] Question: What is the impact of loosening REMS requirements? - The changes are expected to facilitate quicker patient transitions back home, enhancing overall patient experience [93] Question: How is the company addressing delayed neurotoxicity? - The company emphasizes the need for effective bridging therapies to manage tumor burden and reduce adverse events [66] Question: What is the outlook for outpatient administration? - Approximately 50% of patients are currently treated in outpatient settings, with expectations for growth [76]

Core Viewpoint - The company presented Phase I clinical data for cemsidomide in multiple myeloma at the IMS Annual Meeting, indicating progress in clinical development [2][3]. Group 1: Presentation Overview - The conference call was led by Courtney Solberg, Associate Director of Investor Relations, with participation from key executives including Andrew Hirsch, President and CEO, and Len Reyno, Chief Medical Officer [2][3]. - The agenda included opening remarks, a detailed discussion of clinical data for cemsidomide, next steps in clinical development, and a Q&A session with additional participants [3]. Group 2: Clinical Data - Dr. Binod Dhakal, a clinical investigator for multiple myeloma, presented the Phase I clinical results during the IMS meeting [3].

Core Insights - Sanofi's Sarclisa has received approval from the European Commission for the treatment of transplant-eligible newly diagnosed multiple myeloma (NDMM) in combination with bortezomib, lenalidomide, and dexamethasone [1][8] - The approval is based on positive results from the GMMG-HD7 phase 3 study, which demonstrated significant improvements in minimal residual disease (MRD) negativity and progression-free survival (PFS) for patients treated with Sarclisa-VRd compared to VRd alone [2][3][8] Study Details - The GMMG-HD7 study is a pivotal, randomized, open-label, multicenter, two-part phase 3 study evaluating Sarclisa in combination with VRd versus VRd alone in transplant-eligible NDMM patients [6][7] - The study enrolled 662 patients across 67 sites in Germany, with the first part focusing on induction therapy and the second part on maintenance therapy post-transplant [7][8] - The primary endpoints included MRD negativity after induction therapy and PFS after the second randomization post-transplant [8][9] Clinical Results - Sarclisa-VRd showed a statistically significant improvement in MRD negativity, with 53.1% of patients achieving continued MRD negativity compared to 38% in the control arm [3][8] - The final PFS analysis indicated a clinically meaningful improvement in PFS for patients treated with Sarclisa-VRd during induction, regardless of the maintenance therapy received [3][8] Regulatory and Market Position - With this approval, Sarclisa is now recognized as an established treatment option for multiple myeloma, with four approved indications globally, including two in the front-line setting [5][11] - The approval reflects Sanofi's commitment to addressing unmet needs in multiple myeloma care and improving treatment outcomes at every stage of the disease [5][12]

Core Viewpoint - Sanofi's Sarclisa has received approval from the European Commission for the treatment of transplant-eligible newly diagnosed multiple myeloma (NDMM) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) [1][8] Group 1: Approval and Clinical Study - The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on June 19, 2025 [1] - The decision is based on results from the GMMG-HD7 phase 3 study, which showed that Sarclisa-VRd led to a statistically significant minimal residual disease (MRD) negativity benefit at the end of the 18-week induction period [2][8] - The study demonstrated a clinically meaningful improvement in progression-free survival (PFS) for patients treated with Sarclisa-VRd during induction, regardless of the maintenance therapy received [3][8] Group 2: Study Details - The GMMG-HD7 study enrolled 662 patients across 67 sites in Germany, with participants randomized to receive VRd with or without Sarclisa [7] - Sarclisa was administered at a dose of 10 mg/kg through intravenous infusion during the induction phase [7] - The study's primary endpoints included MRD negativity following induction therapy and PFS after post-transplant randomization [8][9] Group 3: Market Position and Future Prospects - Sarclisa is now approved in the EU across all lines of therapy for multiple myeloma, reinforcing its position as an established treatment option [5][8] - The approval reflects Sanofi's commitment to addressing unmet needs in multiple myeloma care and improving treatment outcomes [5][12] - Data from the maintenance portion of the GMMG-HD7 study is forthcoming, which may further support Sarclisa's clinical use [4][8]

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sarclisa in combination with VRd for the treatment of transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, indicating significant progress in addressing unmet patient needs in this area [1][2]. Group 1: Study and Approval Details - The positive CHMP opinion is based on results from the GMMG-HD7 study, which demonstrated a deep and rapid response in transplant-eligible NDMM patients using an anti-CD38-based induction regimen [2][3]. - GMMG-HD7 is the first phase 3 study to show a higher proportion of patients achieving minimal residual disease (MRD) negativity and significant progression-free survival (PFS) benefits post-induction [3][4]. - The study enrolled 662 patients across 67 sites in Germany, with participants receiving three 42-day cycles of VRd, and Sarclisa added to one arm of the study [6][7]. Group 2: Clinical Evidence and Outcomes - The results indicated the highest post-induction and post-transplant MRD negativity rates for any CD38 monoclonal antibody using VRd as a backbone in transplant-eligible NDMM [4][8]. - The primary endpoints of the study included MRD negativity following induction therapy and PFS after post-transplant randomization, with the latter expected to be available later [8][9]. - Secondary endpoints included rates of complete response after induction, overall survival, and safety, with MRD negativity assessed by next-generation flow cytometry [9]. Group 3: Current Approvals and Future Potential - Sarclisa is currently approved in the EU for three indications across different lines of therapy for adult patients with relapsed and/or refractory multiple myeloma and NDMM who are not eligible for transplant [5][10]. - If approved, the new regimen would represent the fourth indication in the EU and the second in the front-line setting globally, enhancing treatment options for transplant-eligible patients [8][10].